Targepeutics

Recent News

Targepeutics, Inc. Announces Patent Issuance For Targeted Brain Cancer Compounds

For Press Release 5/31/2005 - Click Here to view

Targepeutics, Inc. Announces Patent License Agreement with National Institutes of Health

For Press Release 8/17/2005 - Click Here to view

Targepeutics, Inc. Announces New Approaches to Brain Tumor

Therapy consortium (NABTT) Relationship

For Press Release 12/12/2005 - Click Here to view

Targepeutics, Inc. IL-13 Platform Development

For Press Release 1/4/2007 - Click Here to view

Patent Issued
Targepeutics, Inc. announces the issuance of US Patent No. 6,296,843 for its mutated interleukin-13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market). These mutated IL-13 compounds were designed to provide greater specificity toward the IL-13 receptor that is over-expressed in brain tumors. This more specific targeting molecule should allow higher doses, broader application of such compounds, and is expected to reduce the recurrence of tumors produced by affecting untreated tumor cells lying outside of the primary tumor area.

Small Business Innovation Research Award Received from the National Cancer Institute
Targepeutics Inc. is pleased to announce that it has officially received a Small Business Innovative Research (SBIR)grant award from the National Cancer Institute (NCI; www.nci.nih.gov) in the amount of $100,000. We are pleased to have the support of such a reputable and respected organization. This award, which is a phase I award, makes the Company eligible to submit for up to $1 million over the next 2 years in Phase II of the program.

New Approaches to Brain Tumor Therapy (NABTT) Consortium Invitation Extended
NABTT (www.nabtt.org) has offered to conduct GB-13 trials for Targepeutics, Inc. Targepeutics have been officially invited to participate in this exemplary anti-cancer drug development program. This consortium is NCI-funded and includes the following 10 institutions:

Emory University	Johns Hopkins University	University of Texas
University of Alabama	H. Lee Moffitt Cancer Center	Henry Ford Hospital
University of Pennsylvania	Massachusetts General Hospital	Wake Forest University
The Cleveland Clinic

The Consortium consists of oncologists, neurologists, and neurosurgeons working together and with the NIH to rapidly develop and test new treatments for patients with brain tumors. This is a very focused and concerted effort. Clinical protocols aim at fast evaluation of the toxicity and efficacy of experimental therapeutics (Phase I / Phase II clinical trials). The Consortium has large numbers of patients with brain tumors to assure rapid progression through the trials with no delays due to patient recruitment problems. The overall objective of the consortium and of Targepeutics is to improve the management of brain tumors in a foreseeable future.

Musella Brain Tumor Foundation

Targepeutics is proud to announce that it has been chosen to receive a grant from the Musella Foundation for continued development of GB-13. The Musella Foundation For Brain Tumor Research (www.virtualtrials.com) is a non-profit organization dedicated to improving the quality of life and survival times for brain tumor patients. It's major projects include the Clinical Trials & Noteworthy Treatments For Brain Tumors and the Brain Tumor Virtual Trial.